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correct perimembranous ventricular septal defects (pmVSDs) in a prospective, randomized, controlled clinical trial.Background pmVSD is a common congenital heart disease in children. Surgical closure of pmVSD is a well-established therapy
but requires open-heart surgery with cardiopulmonary bypass. Although the transcatheter approach is associated
with signiﬁcant incidence of complete atrioventricular block, it may provide a less invasive alternative. Critical
comparison of the safety and efﬁcacy of the 2 interventions necessitates a prospective, randomized, controlled trial.Methods Between January 2009 and July 2010, 229 children with pmVSD were randomly assigned to surgical or
transcatheter intervention. Clinical, laboratory, procedural, and follow-up data over a 2-year period were compared.Results Neither group had mortality or major complications. However, statistical analysis of the 2 groups demonstrated
signiﬁcant differences (p < 0.001) in minor adverse events (32 vs. 7), quantity of blood transfused, duration of the
procedure, median hospital stay, median intensive care unit stay, median hospitalization cost, and median blood
loss. During a median follow-up of 2 years, the left ventricular end-diastolic dimension of both groups returned
to normal and there was no difference in closure rate, adverse events, and complications between groups.Conclusions Transcatheter device closure and surgical repair are effective interventions with excellent midterm results for
treating pmVSD in children. Transcatheter device closure has a lower incidence of myocardial injury, less blood
transfused, faster recovery, shorter hospital stay, and lower medical expenses. (Transcatheter Closure Versus
Surgery of Perimembranous Ventricular Septal Defects; NCT00890799) (J Am Coll Cardiol 2014;63:1159–68)
ª 2014 by the American College of Cardiology Foundation Open access under CC BY-NC-ND license.Ventricular septal defect (VSD) is the most common type
of congenital heart disease, in which perimembranous
ventricular septal defect (pmVSD) is 1 of the most commonular Surgery, Xijing Hospital, Fourth Military
epartment of Cardiology, Xi’an Children Hos-
f Cardiovascular Surgery, Hanzhong Central
enter at St. Christopher’s Hospital for Children
edicine, Philadelphia, Pennsylvania; and the
ty of Wyoming, Laramie, Wyoming. This trial
ational Natural Science Foundation of China
ll authors have reported that they have no re-
of this paper to disclose. The ﬁrst 5 authors
3; revised manuscript received December 28,subtypes (1–3). Treatment of pmVSD has improved
dramatically over the last 50 years (4–6). Although open-
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1160complications of percutaneous
compared with surgical closure of
VSDs (14–16). On the basis of
these preliminary ﬁndings, we
designed a randomized, controlled
trial to prospectively compare the
safety and efﬁcacy of the 2 inter-
ventions for pmVSD in children.Methods
Patients. Between January 2009
and July 2010, 465 children age
3 to 12 years with pmVSD from
3 major medical centers in
northwest China (Xijing Hospi-
tal, Xi’an; Xi’an Children’s Hos-
pital, Xi’an; and HanzhongCentral Hospital, Hanzhong) were enrolled in the study.
After clinical and transthoracic echocardiographic (TTE)
assessment for eligibility, 236 patients were excluded from the
study and the other 229 were randomly allocated to either the
surgical or transcatheter group (Fig. 1). See details in the
Online Appendix.
Echocardiography. A comprehensive TTE study, which
included M-mode, 2-dimensional, continuous-wave,
pulsed-wave, and color-ﬂow Doppler echocardiography, was
performed prior to operation or intervention and at each
follow-up visit (Fig. 2) (see Online Videos 1, 2, 3, and 4 of
echocardiography screening and follow-up of transcatheter
pmVSD closure). See details in the Online Appendix.
Catheterization. Each patient underwent catheterization
before surgery or transcatheter intervention. Catheterization
was done in the catheterization laboratory with the patients
under conscious sedation and local anesthesia. Hemody-
namic parameters, including pulmonary arterial, aortic,
atrial, and ventricular pressures, were recorded, and oxi-
metric values were measured in the cardiac chambers and
vessels, based on which pulmonary-to-systemic ﬂow ratio
(Qp/Qs) was calculated.
Occluding device. The Shanghai pmVSD occluder (Lepu
Medical Technology Co., Ltd., Beijing, China) (Fig. 3) was
used in this study (11,15). See details in theOnline Appendix.
Transcatheter device implantation. Transcatheter inter-
vention was described in previous reports (15,16) (see
Online Videos 5, 6, 7, 8, 9, 10, 11, and 12 of transcatheter
pmVSD closure of different kinds of pmVSD). See details in
the Online Appendix.
Surgical procedure. The surgical closure was performed
with the patient under general anesthesia the second day
after catheterization. The chest was opened through a
standard median sternotomy. Depending on the size of the
pmVSD, direct-suture, Dacron, or pericardium patch was
used to repair the defect. All patients were transferred to the
intensive care unit for further treatment. See details in the
Online Appendix.Follow-up protocol. All patients were followed up for
2 years. Each patient underwent serial follow-up at 3 days,
3 months, 6 months, 1 year, and 2 years following inter-
vention or surgery. See details in the Online Appendix.
Laboratory tests. The biochemical assays included mea-
surement of levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), blood urea nitrogen
(BUN), creatinine, cardiac troponin I (cTnI), and creatine
kinase-MB (CK-MB) at the induction of anesthesia and 1,
3, 6, 12, 24, and 72 h after pmVSD occluder deployment/
aorta cross-clamp removal. See details in the Online
Appendix.
Statistical analysis. See details in the Online Appendix.Results
Trial proﬁle. The sample size needed for this study was
calculated, assuming the largest difference between treat-
ment groups. With a signiﬁcance level of 0.05 and a power
of 80%, we calculated the needed number of events to be
35 in each group. We also determined that a minimum of
43 patients in each group was necessary to conduct the
present study.
The patients were followed up until June 2012, with a
median follow-up of 2 years (2 to 40 months). During this
period, 29 patients withdrew from the study. A total of 101
patients in the transcatheter group and 99 patients in the
surgery group completed follow-up examinations. The trial
proﬁle is shown in Figure 1. The 2 groups were well
matched for baseline characteristics (Table 1).
Baseline characteristics. The 2 groups had comparable
baseline characteristics (Table 1) with regard to age, sex,
weight, clinical manifestations, echocardiographic data, and
invasive data. Twenty-ﬁve patients in the surgery group and
28 in the transcatheter group had Qp/Qs values below
1.5:1. Among them, 17 patients in the surgery group and
21 in the transcatheter group had no left ventricular
enlargement (Z-score <þ2). These patients were enrolled
mainly because they had symptoms such as refractory
pneumonia, congestive heart failure, delayed growth, exer-
cise intolerance, frequent colds, or unyielding parental re-
quests. The average age at closure was 5.8  2.4 years and
5.5  2.6 years, respectively (p ¼ 0.398). Most patients
(56.6% in the surgery group and 65.3% in the transcatheter
group; p ¼ 0.531) were treated because of hemodynamic
changes. The mean defect size was 5.9  5.3 mm and 5.2 
6.1 mm in the surgical and transcatheter groups, respectively
(p ¼ 0.866).
Transcatheter versus surgical treatment. The operative
characteristics and outcomes in patients according to treat-
ment are summarized in Table 1. In both groups, no mor-
tality, stroke, or neurological deﬁcit was observed. According
to ventriculographic examination of the left ventricle,
pmVSD was classiﬁed as tubular (n ¼ 24), window-like
(n ¼ 5), aneurysmal (n ¼ 33), or infundibular (n ¼ 37) in
the surgery group, a distribution that was comparable to
Figure 1 Trial Design and Proﬁle
A total of 465 children with perimembranous ventricular septal defect (pmVSD) were enrolled, and 236 patients were excluded after assessment for eligibility. A total of 229
were randomly allocated to the surgical or transcatheter group, and 29 patients withdrew from the study. A total of 101 patients in the transcatheter group and 99 patients in the
surgery group completed follow-up examinations.
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1161that in the transcatheter group. The average procedural time
in the surgery group was 180.5  66.1 min, with an average
cardiac arrest time of 24.2  15.4 min and an average
cardiopulmonary bypass time of 55.1  32.0 min. In the
group receiving surgery, 75 patients were repaired with a
Dacron or pericardium patch and 24 patients with primary
closure. One major adverse event occurred in the surgery
group (i.e., bleeding occurred following operation in a
7-year-old girl that required thoracic re-exploration). Several
minor adverse events were reported. Blood loss that required
blood transfusion occurred in 23 patients. Prior to discharge,
2 patients experienced a residual shunt through the rim
of the VSD patch, as demonstrated by color-ﬂow Doppler
mapping. Furthermore, 2 patients developed new or in-
creased tricuspid valvular regurgitation <2 grades and were
followed without further intervention. Other minor adverse
events in the surgery group included 3 right bundle-branch
blocks and 1 partial left bundle-branch block (Table 2). Twopatients were found to display a prolonged PR interval
(>0.02 s) after surgical closure and before discharge.
In the transcatheter group, device deployment was suc-
cessful in all patients. The mean defect size measured by
TTE was 5.2  6.1 mm, and the mean size of the occluder
was 7.4 mm. The Shanghai pmVSD device was used for all
patients. The mean ﬂuoroscopy time was 8.2  3.4 min, and
the total procedural time was 38.2  24.6 min. A mean of
42.7  6.6 ml of contrast was used. Based on ventriculo-
graphic results (12,16), pmVSD was classiﬁed as tubular
(n ¼ 27), window-like (n ¼ 2), aneurysmal (n ¼ 26), or
infundibular (n ¼ 46). The transcatheter procedure failed
with the ﬁrst occluder in 3 patients, but a second device was
deployed successfully in all of them. No major adverse event
was observed in the transcatheter group, and none of the
patients required a transfusion as a result of blood loss.
There were 7 minor adverse events, including 1 hematoma
of the groin, 1 right bundle-branch block, 2 junctional
Figure 2 TTE Images Showing 4 Types of pmVSD
(A) Two-dimensional image of a window-shaped perimembranous ventricular septal defect (pmVSD). (B) Color-ﬂow Doppler image showing left-to-right shunt through pmVSD
(same patient as in A). (C) Two-dimensional image of a tubular-shaped pmVSD. (D) Color-ﬂow Doppler image showing left-to-right shunt through pmVSD (same patient as in C).
(E) Two-dimensional image of an infundibular-shaped pmVSD. (F) Color-ﬂow Doppler image showing left-to-right shunt through pmVSD (same patient as in E). (G) Two-
dimensional image of an aneurysmal-shaped pmVSD. (H) Color-ﬂow Doppler image showing left-to-right shunt through pmVSD (same patient as in G). Yellow arrows indicate
pmVSD. TTE ¼ transthoracic echocardiography/echocardiographic. See Online Videos 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12.
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1162rhythms, 1 partial left bundle-branch block, 1 residual shunt
before discharge, and 1 new case of mild tricuspid valve
regurgitation. Five patients had a prolonged PR interval
(>0.02 s) following transcatheter closure before discharge,
which was not signiﬁcantly different than that of the surgery
group (p ¼ 0.260). All of the patients were asymptomatic
and did not require further treatment.Figure 3 Shanghai pmVSD Occluder
(A) Front view. (B) Back view. (C) Lateral view. pmVSD = perimembranous ventricular seOverall, there were 32 minor adverse events in the
surgery group (32.3%) and 7 in the transcatheter group
(6.9%). The Fisher exact test showed a signiﬁcant dif-
ference in minor adverse events between the 2 groups
(p < 0.001).
Laboratory data. The levels of ALT in the surgery group
began to increase 1 h after removal of the aortic cross-clampptal defect.
Table 1
Baseline Characteristics, Laboratory Data, Procedural Details, and
Clinical Outcomes at 2-Year Follow-Up
Surgery Group Transcatheter Group p Value
Sample size 99 101
Age, yrs 5.8  2.4 5.5  2.6 0.398
Boys 61 50 0.085
Weight, kg 20.5  12.4 22.1  13.8 0.390
Patients with low weight for age 25 (25.3) 28 (27.7) 0.692
Clinical manifestations
Clinical symptoms 35 28
Hemodynamic changes 56 66
Heart murmur with clinical ﬁndings 7 6
Previous IE 1 1
Echocardiographic data
Defect size, mm 5.9  5.3 5.2  6.1 0.388
LA dimension, mm 21.5  4.3 20.7  3.8 0.220
LVEDD, mm 54.6  15.3 51.4  16.8 0.161
LVEDD Z-score þ1.8  1.5 þ1.7  1.4 0.493
Invasive data
RA mean pressure, mm Hg 4.8  4.2 5.2  4.7 0.527
RV end-diastolic pressure, mm Hg 7.8  9.3 6.4  12.5 0.371
PA systolic pressure, mm Hg 35.6  11.4 33.6  9.8 0.185
PA diastolic pressure, mm Hg 13.6  4.8 12.8  4.3 0.216
PA mean pressure, mm Hg 19.2  7.4 18.1  6.8 0.275
Qp/Qs 2.3  2.2 2.5  2.7 0.567
Procedural details
Blood transfusion, ml 213.2 (298.7) 0 <0.001
Patient received transfusion 19 0 <0.001
Procedural duration, min 180.5  66.1 38.2  24.6 <0.001
Hospital stay after intervention, days 7.2  5.7 3.3  1.6 <0.001
ICU stay, h 20.1 (22.6) 0 <0.001
Hospitalization cost, US$ equivalent 4,846.3  1,628.1 3,550.4  745.9 <0.001
Blood loss, ml 211.6 (197.3) 47.6 (25.8) <0.001
Time to return to normal activities, days 17.6 (19.3) 3.5 (7.1) <0.001
Values are n, mean  SD, or n (%).
ICU ¼ intensive care unit; IE ¼ infective endocarditis; LA ¼ left atrium; LVEDD ¼ left ventricular end-diastolic dimension; PA ¼ pulmonary artery;
Qp/Qs ¼ pulmonary-to-systemic ﬂow ratio; RA ¼ right atrium; RV ¼ right ventricular.
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1163and peaked at 24 h. ALT levels in the transcatheter group
remained unchanged after the procedure. A comparison of
ALT levels between the 2 groups displayed a signiﬁcant
difference at 1 and 24 h following pmVSD closure
(p < 0.01). The trends of changes in AST levels were the
same as those for ALT. There were also signiﬁcant differ-
ences in the AST levels at 1 and 24 h following pmVSD
repair (p < 0.01). BUN levels in the surgery group rose 1 h
after removal of the aortic cross-clamp. The BUN level in
the transcatheter group remained constant. There was no
signiﬁcant difference in BUN level alteration between the 2
groups at any time after pmVSD closure. Creatinine levels
showed a more signiﬁcant increase in the surgery group than
in the transcatheter group during the 24 h after the proce-
dure (p < 0.01) (Fig. 4).
The concentrations of CK-MB and cTnI before inter-
vention were normal in both groups. In the surgery group,
CK-MB levels peaked after 24 h, whereas cTnI levels
began to rise after aortic clamping and peaked 12 h later.
The levels of cTnI did not return to normal even 72 hafter declamping. In the transcatheter group, both the
CK-MB and cTnI levels remained unchanged after the
deployment of the device. The 0- to 72-h area under
the curve of CK-MB and cTnI release was signiﬁcantly
higher in the surgery group than in the transcatheter
group (3,415.8 vs. 425.1 and 597.6 vs. 4.7, respectively;
p < 0.001) (Fig. 5). No hemoglobinuria was detected in
either group.
Echocardiography. TTE examination revealed that 97 of
the 99 pmVSDs in the surgery group were completely closed
3 days following the operation and before discharge (Fig. 6).
Two patients had residual shunts at the rim of the patch,
measuring 1 and 1.5 mm by color-ﬂow Doppler mapping.
Two patients in the surgery group had mild tricuspid
insufﬁciencies.
In the transcatheter group, a shunt that measured<2ml by
ventriculography through the occluder was noted in 28 of the
101 patients (27.7%). One patient got a residual shunt before
discharge, and all shunts diminished at the 3-month follow-
up. One patient developed new tricuspid insufﬁciency
Table 2
Major and Minor Adverse Events Observed in
Device Compared With Surgical Closure Groups
Transcatheter
Group
(n ¼ 101)
Surgery
Group
(n ¼ 99) p Value
Major adverse events 0 1 1
Death 0 0
Complete atrioventricular block 0 0
New-onset valvular regurgitation
that required surgical repair
0 0
Thoracic re-exploration 0 1
Minor adverse events 7 31 <0.001
Hematoma of the groin 1 0
Blood transfusion
because of blood loss
0 23
Residual shunt before discharge 1 2
Left bundle-branch block 1 1
Right bundle-branch block 1 3
Junctional rhythm 2 0
New or increased valvular
regurgitation <2 grades
1 2
Total 7 32 <0.001
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1164(3-mm vena contracta by color-ﬂow Doppler mapping). The
patient was asymptomatic and was followed closely.
Two-year follow-up and clinical outcomes. All of the 101
patients in the transcatheter group and 99 patients in theFigure 4 Laboratory Data for the 2 Groups Within 72 h of pmVSD Cl
(A) Alanine aminotransferase (ALT) levels. (B) Aspartate aminotransferase (AST) levels.
presented as mean  SD (range bars). **p < 0.01 between the 2 groups. pmVSD ¼ persurgery group were followed for a median duration of
2 years. No mortality, neurological deﬁcits, thromboembo-
lism, or endocarditis were reported in either group. All
patients displayed New York Heart Association functional
class I to II with a normal sinus rhythm. Echocardio-
graphically, the Z-scores of the left ventricular end-diastolic
dimension decreased from 1.8  1.5 to 0.8  0.6 in the
surgery group (p < 0.001) and from 1.7  1.4 to 0.7  0.8
(p < 0.001) in the transcatheter group at the 2-year follow-
up. Comparison of Z-scores showed no statistical sig-
niﬁcance between the catheter and surgical groups either
before (p¼ 0.626) or after the procedure (p¼ 0.319) (Fig. 7).
In the surgery group, 1 patient with a residual shunt
experienced spontaneous pmVSD closure at the 2-year
follow-up. Another patient had a small residual VSD
shunt (1.5 mm) but was asymptomatic. No further inter-
vention was indicated. The 2 patients with tricuspid valve
insufﬁciency still had mild regurgitation but did not require
intervention. Six patients had arrhythmias at the 2-year
follow-up, including 4 with right bundle-branch block and
2 with partial left bundle-branch block. In the transcatheter
group, all pmVSDs were closed at the 2-year follow-up,
which was conﬁrmed echocardiographically by the stable
position of the device and the lack of a residual VSD shunt.
At the 1-year follow-up, the patient who had a residual shuntosure
(C) Blood urea nitrogen (BUN) levels. (D) Creatinine (CRE) levels. Data are
imembranous ventricular septal defect; S ¼ surgical group; T ¼ transcatheter group.
Figure 5 Changes in Myocardial Injury Indexes Between the 2 Groups
(A) Serum cardiac troponin I (cTnI) release during the 72 h following pmVSD repair. (B) Creatine kinase–MB (CK-MB) release during the 72 h following pmVSD repair. Area under
the curve (arbitrary units) of serum cTnI release was measured in both groups. Data are presented as mean  SD (range bars). **p < 0.01 between the 2 groups. Abbreviations
as in Figures 1 and 4.
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1165prior to discharge exhibited no left-to-right shunt across the
interventricular septum. Overall, 5 patients had arrhythmias,
including 1 with right bundle-branch block, 3 with junctional
rhythms (1 additional patient developed junctional rhythm at
the 3-month follow-up), and 1 complete left bundle-branch
block. The patient with mild post-interventional tricuspid
regurgitation was asymptomatic and required no further
treatment. During a median follow-up of 2 years, noFigure 6
2-Year Echocardiographic Follow-Up Displaying Intact Ventr
Transcatheter Group
(A) Two-dimensional, 4-chamber view. (B) Two-dimensional and color-ﬂow Doppler mapp
Doppler mapping. VSD ¼ ventricular septal defect.differences were observed in the closure rate, adverse events,
or complications between the 2 groups.
Discussion
In developing countries, many children with congenital
heart disease are waiting to be treated. Among congenital
heart diseases, pmVSD is perhaps the most common,icular Septum Without Residual VSD Shunt in the
ing image. (C) Two-dimensional, short-axis view. (D) Two-dimensional and color-ﬂow
Figure 7 Z-Score Alterations Among Groups
At 2-year follow-up, the Z-scores of the left ventricular end-diastolic dimension
decreased from 1.8  1.5 to 0.8  0.6 in the surgery group (p < 0.001) and from
1.7  1.4 to 0.7  0.8 (p < 0.001) in the transcatheter group. Comparison of
Z-score between surgery and transcatheter groups showed no statistical signiﬁ-
cance before procedure (p ¼ 0.626) and after procedure (p ¼ 0.319). *p < 0.001
between the pre-surgical intervention (S-Pre) and post-surgical intervention (S-Post)
groups. #p < 0.001 between the pre-transcatheter intervention (T-Pre) and post-
transcatheter intervention (T-Post) groups. Data expressed as mean  SE.
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1166accounting for almost one-ﬁfth of all defects. There is an
immediate need for an economical, effective, less-invasive
technique. In 2002, Hijazi et al. (17) ﬁrst closed pmVSDs
using an Amplatzer membranous VSD occluder. Whether
this less-invasive approach may replace open-heart surgery as
the treatment of choice is debatable. Over the past decade,
the Amplatzer occluder has been proven to be superior to
previous devices, such as the Gianturco coils (Cook Inc.,
Bloomington, Indiana), the Rashkind device (USCI An-
giographics, Billerica, Massachusetts), and Sideris immedi-
ate release patch (Custom Medical Devices, Athens, Greece)
(18–20), in closing congenital heart defects. However, the
Amplatzer pmVSD occluder has been associated with a
relatively high risk of complete atrioventricular block;
consequently, the sponsor voluntarily stopped the U.S.
clinical study (5,10,21,22). In recent years, similar devices
from China have been adopted in developing countries with
good results (23,24). Interest is growing as towhether this new
technique can replace traditional open-heart surgery as the
“gold standard” for treatment of pmVSD. Therefore, we
designed this randomized, controlled trial as a prospective
comparison of the 2 treatments for children with pmVSD.
Both transcatheter device closure and surgical repair have
achieved excellent midterm results for children with
pmVSD. Safety and efﬁcacy are considered in terms of
success of the procedure, complications, cost, hospital stay,
and time to return to normal activities. There was no
mortality or complete atrioventricular block in either group.
Minor complications, such as residual shunt, arrhythmia,
and valve insufﬁciency, were minimal in both groups.
Our results showed that the Z-score of the left ventricularend-diastolic dimension of both groups returned to normal
at the 2-year follow-up, and compared with open-heart
surgical repair, transcatheter device closure possesses several
advantages, including no requirement for intensive care unit
stay, shorter procedural time, less blood loss, lower medical
expenses, and a much faster recovery time (Table 1).
We found that tubular, window, and infundibular types of
pmVSD were technically easier to repair using transcatheter
intervention and had few complications. Several technical
issues were crucial to the overall success of transcatheter
pmVSD closure, especially for the aneurysmal type. First,
crossing the pmVSD was the most crucial step toward
successful transcatheter closure and was especially chal-
lenging for the aneurysmal type of pmVSD. In such cir-
cumstances, selection of different types of catheters (e.g.,
right Judkins, 3DRC, or partly-cut pigtail catheter) and
different wires may be helpful. Second, for the aneurysmal
type of pmVSD, placing the occluder inside the aneurysmal
sac at all times was an important step for minimizing heart
rhythm disturbances and complications (Online Video 10).
In our series, occluders were placed away from the ventric-
ular septum and inside the aneurysmal tissue in 23 of
26 patients with aneurysmal pmVSD. Meanwhile, given
that aneurysmal tissues were often adjacent to or even part of
the tricuspid valve, caution should be taken when the
operator passes the wire and catheter through the tricuspid
valve to establish the arteriovenous circuit. Furthermore,
detection of new tricuspid regurgitation using TTE was
routinely carried out before the occluder was released. Third,
selection of the size of the device is important for a suc-
cessful transcatheter pmVSD intervention. We recom-
mended previously that the relationship between occluder
size (y) and pmVSD size (x) as measured by ventriculog-
raphy was y ¼ 0.966x þ 2.073, R2 ¼ 0.967 (17). An
oversized device (150% over the calculated size) should be
avoided to prevent possible complete atrioventricular block
and valve impingement. Finally, strict adherence to the in-
clusion and exclusion criteria for transcatheter pmVSD
closure is crucial to the overall success of the intervention.
We excluded patients with low body weight (<10 kg) and
those younger than age 3 years to ensure higher success rates
and fewer complications.
We chose cTnI to evaluate myocardial injury. Although
cTnI has been used routinely to assess myocardial injury in
open-heart surgery, little information is available regarding
the changes in cTnI levels in transcatheter pmVSD closure.
The results of our study have contributed to the current
literature and indicate the remarkable advantage of trans-
catheter intervention over surgical repair in preventing
myocardial injury. By obviating the need for the ischemia-
reperfusion process and diminishing the side effects of car-
diopulmonary bypass, the transcatheter closure technique
remarkably decreased myocardial injury associated with open
surgical repair of pmVSD.
Although our 2-year follow-up study showed excellent
midterm outcomes in treating pmVSD in children,
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1167indications for intervention in children are based on clinical,
echocardiographic, and catheterization data. We excluded
patients who presented with small defects without hemo-
dynamic changes or symptoms due to the possibility of
spontaneous closure and good life-long survival. We also
excluded patients whose anatomy was not suitable for
transcatheter closure. These patients were referred directly
for surgical repair. In addition, a Qp/Qs ratio of 1.5:1 to
2.5:1, or evidence of increased left ventricular overload,
is an indication for closure. The beneﬁts of avoiding car-
diopulmonary bypass, reducing the psychological impact,
and offering the less painful and less uncomfortable percu-
taneous intervention are extremely attractive for both
patients and physicians (3,7,25). Recently, clinical trials
with the new Amplatzer membranous VSD occluder 2
and Amplatzer duct occluder II device (AGA Medical
Corporation, Plymouth, Minnesota) have demonstrated
promising results in initial studies (26–28). With more
reﬁnement to the devices and new clinical trials for patients
with pmVSD, the treatment of choice is likely to be updated
frequently.
Study limitations. First, as in our previous study and in
accordance with the consensus of Chinese experts (29), we
followed strict inclusion/exclusion criteria. Only children >3
years of age were enrolled. Also, because of the design of this
study, we only evaluated the results of children <12 years of
age; adult patients were excluded. Second, according to the
design of the study, patients with small defects without
hemodynamic changes or symptoms and patients whose
anatomy was not suitable for transcatheter closure were
excluded from the current study (i.e., the results of the
current study cannot be applied to all kinds of patients with
pmVSD). Third, the patients were enrolled from 3 large-
volume centers in northwest China and may not be repre-
sentative with respect to ethnicity and other factors. Last,
the number of patients was relatively small, and the 2-year
follow-up period was short. Additional data are required
to evaluate the 2 procedures longitudinally.Conclusions
We demonstrated that both transcatheter device closure and
surgical repair are effective treatments, with excellent mid-
term outcomes, for pmVSD in children who met our in-
clusion criteria. In our study, compared with surgical repair,
transcatheter device closure had fewer myocardial injuries,
fewer transfusions, shorter hospital stays, reduced medical
costs, and faster recovery times. Therefore, transcatheter de-
vice closure is the treatment of choice for pmVSD in children
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APPENDIX
For a supplemental methods section as well as videos and their legends,
please see the online version of this article.
